STK35 and colorectal carcinoma: In this study, we observed that STK35 overexpression could partly counteract the anti-CRC functions induced by the AKT inhibitor MK-2206, further illustrating that STK35 may promote the activities of CRC cells via its regulatory effect on the AKT pathway.